Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""chemotherapy"" wg kryterium: Temat


Starter badań:

Tytuł :
Survival Response of Patients With Gastric Cancer Treated With Regional Arterial-Perfusion Chemotherapy Is Correlated With Borrmann Classification.
Autorzy :
Ma YE; College of Medical Imaging, Xuzhou Medical University, Xuzhou, P.R. China.
Liang X; College of Medical Imaging, Xuzhou Medical University, Xuzhou, P.R. China.
Liu LI; Department of Interventional Therapy, Department of Radiology, Jinling Hospital, Nanjing, P.R. China.
Gao D; Department of Interventional Therapy, Department of Radiology, Jinling Hospital, Nanjing, P.R. China.
Yang T; College of Medical Imaging, Xuzhou Medical University, Xuzhou, P.R. China.; Department of Interventional Therapy, Department of Radiology, Jinling Hospital, Nanjing, P.R. China.
Hoffman RM; AntiCancer Inc., San Diego, CA, U.S.A.; Department of Surgery, UCSD, San Diego, CA, U.S.A.
Xu J; College of Medical Imaging, Xuzhou Medical University, Xuzhou, P.R. China; .; Department of Interventional Therapy, Department of Radiology, Jinling Hospital, Nanjing, P.R. China.
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2021 Nov; Vol. 41 (11), pp. 5507-5515.
Typ publikacji :
Journal Article
MeSH Terms :
Chemotherapy, Cancer, Regional Perfusion*/adverse effects
Chemotherapy, Cancer, Regional Perfusion*/mortality
Neoadjuvant Therapy*/adverse effects
Neoadjuvant Therapy*/mortality
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Stomach Neoplasms/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemotherapy, Adjuvant ; Female ; Gastrectomy ; Humans ; Lymph Node Excision ; Male ; Margins of Excision ; Middle Aged ; Neoplasm Staging ; Retrospective Studies ; Stomach Neoplasms/mortality ; Stomach Neoplasms/pathology ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Peritoneal Spread of Low-grade Appendiceal Tumours - 2 Days of Early Postoperative Intra-peritoneal Chemotherapy Are Enough.
Autorzy :
Rao A; Department of Surgery, University of New South Wales, St George Hospital, Kogarah, NSW, Australia.
Mui J; Department of Surgery, University of New South Wales, St George Hospital, Kogarah, NSW, Australia.
Barat S; Department of Surgery, University of New South Wales, St George Hospital, Kogarah, NSW, Australia.
Matar AA; Department of Surgery, University of New South Wales, St George Hospital, Kogarah, NSW, Australia.
Alzahrani N; Department of Surgery, University of New South Wales, St George Hospital, Kogarah, NSW, Australia.; College of Medicine, Imam Muhammad Ibn Saud Islamic University, Riyadh, Kingdom of Saudi Arabia.; Department of Surgery, National Guard Health Affairs, King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia.
Morris DL; Department of Surgery, University of New South Wales, St George Hospital, Kogarah, NSW, Australia; .
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2021 Nov; Vol. 41 (11), pp. 5569-5575.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Cytoreduction Surgical Procedures*/adverse effects
Cytoreduction Surgical Procedures*/mortality
Hyperthermic Intraperitoneal Chemotherapy*/adverse effects
Hyperthermic Intraperitoneal Chemotherapy*/mortality
Appendiceal Neoplasms/*therapy
Peritoneal Neoplasms/*therapy
Pseudomyxoma Peritonei/*therapy
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Appendiceal Neoplasms/mortality ; Appendiceal Neoplasms/pathology ; Chemotherapy, Adjuvant ; Databases, Factual ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Peritoneal Neoplasms/mortality ; Peritoneal Neoplasms/secondary ; Pseudomyxoma Peritonei/mortality ; Pseudomyxoma Peritonei/secondary ; Retrospective Studies ; Time Factors ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Multicenter Randomized Phase 2 Trial Comparing Chemoradiotherapy and Docetaxel Plus 5-Fluorouracil and Cisplatin Chemotherapy as Initial Induction Therapy for Subsequent Conversion Surgery in Patients With Clinical T4b Esophageal Cancer: Short-term Results.
Autorzy :
Sugimura K; Department of Surgery, Osaka International Cancer Institute, Osaka, Japan.
Miyata H; Department of Surgery, Osaka International Cancer Institute, Osaka, Japan.
Tanaka K; Departments of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Makino T; Departments of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Takeno A; Department of Surgery, Kansai Rosai Hospital, Hyogo, Japan.
Shiraishi O; Department of Surgery, Kindai University Faculty of Medicine, Osaka Sayama, Osaka, Japan.
Motoori M; Department of Surgery, Osaka General Medical Center, Osaka, Japan.
Yamasaki M; Departments of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Kimura Y; Department of Surgery, Kindai University Faculty of Medicine, Osaka Sayama, Osaka, Japan.
Hirao M; Department of Surgery, National Hospital Organization, Osaka National Hospital, Osaka, Japan.
Fujitani K; Department of Surgery, Osaka General Medical Center, Osaka, Japan.
Yasuda T; Department of Surgery, Kindai University Faculty of Medicine, Osaka Sayama, Osaka, Japan.
Mori M; Department of Surgery and Science, Graduate School of Medical Sciences, Kyusyu University, Japan.
Eguchi H; Departments of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Yano M; Department of Surgery, Osaka International Cancer Institute, Osaka, Japan.
Doki Y; Departments of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Pokaż więcej
Źródło :
Annals of surgery [Ann Surg] 2021 Dec 01; Vol. 274 (6), pp. e465-e472.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Chemoradiotherapy*/adverse effects
Induction Chemotherapy*/adverse effects
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cisplatin/*therapeutic use
Docetaxel/*therapeutic use
Esophageal Squamous Cell Carcinoma/*therapy
Fluorouracil/*therapeutic use
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cisplatin/adverse effects ; Docetaxel/adverse effects ; Esophageal Squamous Cell Carcinoma/pathology ; Esophageal Squamous Cell Carcinoma/surgery ; Esophagectomy/adverse effects ; Female ; Fluorouracil/adverse effects ; Humans ; Lymph Node Excision/adverse effects ; Male ; Middle Aged ; Neoplasm Staging ; Postoperative Complications ; Prospective Studies
Czasopismo naukowe
Tytuł :
Clinical impact of primary tumour ImIBG response to induction chemotherapy in children with high-risk neuroblastoma.
Autorzy :
Szychot E; Clinical Studies, The Institute of Cancer Research, Sutton, UK. .; Oak Centre for Children and Young People, Royal Marsden Hospital, Sutton, SM2 5PT, UK. .; Department of Paediatrics, Paediatric Oncology and Immunology, Pomeranian Medical University, Szczecin, Poland. .
Morgenstern D; Departments of Haematology/Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.; Hospital for Sick Children, Toronto, Canada.
Chopra M; Department of Radiology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Sorrentino S; Department of Radiology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.; Unit of Paediatric Oncology, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Arthurs O; Department of Radiology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Sebire N; Department of Pathology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Arfeen F; Department of Radiology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Brodkiewicz A; Department of Paediatrics, Child's Nephrology, Dialysis Therapy and Acute Poisoning, Szczecin, Poland.
Humphries P; Department of Radiology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Biassoni L; Department of Radiology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Pokaż więcej
Źródło :
International journal of clinical oncology [Int J Clin Oncol] 2022 Jan; Vol. 27 (1), pp. 253-261. Date of Electronic Publication: 2021 Oct 09.
Typ publikacji :
Journal Article
MeSH Terms :
Induction Chemotherapy*
Neuroblastoma*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Infant ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up.
Autorzy :
Zheng F; Department of Medical Oncology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Beijing, 100021, China.
Du F; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), The VIPII Gastrointestinal Cancer Division of Medical Department, Peking University Cancer Hospital and Institute, Beijing, 100021, China.
Wang W; Department of Pathology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Wang Y; Shandong Cancer Hospital/Institute, Jinan, 250117, Shandong, China.
Li M; Beijing Luhe Hospital, Capital Medical University, Beijing, 101100, China.
Zhao J; Breast Disease Diagnosis and Treatment Center, Affiliated Hospital of Qinghai University and Affiliated Cancer Hospital of Qinghai University, Xining, 810000, China.
Wang X; Department of VIP Medical Services, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Yue J; Department of VIP Medical Services, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Wang J; Department of Medical Oncology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Beijing, 100021, China.
Yang Z; Department of Medical Oncology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Beijing, 100021, China.
Cai R; Department of Medical Oncology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Beijing, 100021, China.
Ma F; Department of Medical Oncology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Beijing, 100021, China.
Fan Y; Department of Medical Oncology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Beijing, 100021, China.
Li Q; Department of Medical Oncology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Beijing, 100021, China.
Zhang P; Department of Medical Oncology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Beijing, 100021, China.
Xu B; Department of Medical Oncology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Beijing, 100021, China. .
Yuan P; Department of Medical Oncology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Beijing, 100021, China. .; Department of VIP Medical Services, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. .
Pokaż więcej
Źródło :
Breast cancer research and treatment [Breast Cancer Res Treat] 2022 Jan; Vol. 191 (1), pp. 97-105. Date of Electronic Publication: 2021 Oct 14.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Triple Negative Breast Neoplasms*/drug therapy
Carboplatin/adverse effects ; Chemotherapy, Adjuvant ; Cyclophosphamide/adverse effects ; Epirubicin/adverse effects ; Female ; Follow-Up Studies ; Humans ; Paclitaxel/adverse effects ; Taxoids/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
What is the best treatment recommendation for HER2+ IBC with residual disease?-a narrative review.
Autorzy :
Zakon DB; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Valero V; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło :
Chinese clinical oncology [Chin Clin Oncol] 2021 Dec; Vol. 10 (6), pp. 59.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*
Breast Neoplasms*/drug therapy
Ado-Trastuzumab Emtansine ; Chemotherapy, Adjuvant ; Female ; Humans ; Neoadjuvant Therapy ; Receptor, ErbB-2 ; Trastuzumab/therapeutic use
Czasopismo naukowe
Tytuł :
Is there an optimal adjunct therapy to traditional cytotoxic induction?
Autorzy :
Michaelis LC; Medical College of Wisconsin, Froedtert Hospital, WI, 53266, USA. Electronic address: .
Pokaż więcej
Źródło :
Best practice & research. Clinical haematology [Best Pract Res Clin Haematol] 2021 Dec; Vol. 34 (4), pp. 101326. Date of Electronic Publication: 2021 Oct 23.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Cytarabine/therapeutic use ; Daunorubicin/therapeutic use ; Humans ; Idarubicin/therapeutic use ; Induction Chemotherapy ; Remission Induction
Czasopismo naukowe
Tytuł :
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.
Autorzy :
Jaramillo S; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany. .
Krisam J; Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
Le Cornet L; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.
Kratzmann M; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.
Baumann L; Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
Sauer T; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Crysandt M; Department of Medicine IV, Aachen University Hospital, Aachen, Germany.
Rank A; Department of Medicine II, Augsburg University Hospital, Augsburg, Germany.
Behringer D; Department of Hematology, Oncology and Palliative Medicine, Augusta Hospital Bochum, Bochum, Germany.
Teichmann L; Department of Medicine and Polyclinic III, Bonn University Hospital, Bonn, Germany.
Görner M; Department of Hematology, Oncology and Palliative Medicine, Community Hospital Bielefeld, Bielefeld, Germany.
Trappe RU; Department of Medicine II, Prot. Diaconal Hospital Bremen, Bremen, Germany.
Röllig C; Department of Internal Medicine I, TU Dresden University Hospital, Dresden, Germany.
Krause S; Department of Medicine V, Erlangen University Hospital, Erlangen, Germany.
Hanoun M; Department of Hematology, Essen University Hospital, Essen, Germany.
Hopfer O; Department of Medicine I, Hospital Frankfurt (Oder), Frankfurt (Oder), Germany.
Held G; Department of Internal Medicine I, Westpfalz Hospital Kaiserslautern, Kaiserslautern, Germany.
Buske S; Department of Medicine II, Community Hospital Kiel, Kiel, Germany.
Fransecky L; Department of Internal Medicine II, Schleswig-Holstein University Hospital Kiel, Kiel, Germany.
Kayser S; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.; Department of Medicine I - Hematology and Cell Therapy, Leipzig University Hospital, Leipzig, Germany.
Schliemann C; Department of Medicine A, Münster University Hospital, Münster, Germany.
Schaefer-Eckart K; Department of Internal Medicine V, North Hospital Nürnberg, Nürnberg, Germany.
Al-Fareh Y; Department of Hematology and Oncology, St. Josef Brothers' Hospital Paderborn, Paderborn, Germany.
Schubert J; Department of Internal Medicine II, Elbland Hospital Riesa, Riesa, Germany.
Geer T; Department of Medicine II, Diaconal Hospital Schwäbisch-Hall, Schwäbisch Hall, Germany.
Kaufmann M; Department of Hematology, Oncology and Palliative Medicine, Robert-Bosch Hospital Stuttgart, Stuttgart, Germany.
Brecht A; Department of Internal Medicine II, Helios Dr. Horst Schmidt Hospital Wiesbaden, Wiesbaden, Germany.
Niemann D; Department of Internal Medicine, Hematology, Oncology and Palliative Medicine, Prot. Monastery Hospital St. Jakob Koblenz, Koblenz, Germany.
Kieser M; Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
Bornhäuser M; Department of Internal Medicine I, TU Dresden University Hospital, Dresden, Germany.
Platzbecker U; Department of Medicine I - Hematology and Cell Therapy, Leipzig University Hospital, Leipzig, Germany.
Serve H; Department of Hematology/Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany.
Baldus CD; Department of Internal Medicine II, Schleswig-Holstein University Hospital Kiel, Kiel, Germany.
Müller-Tidow C; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Schlenk RF; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.
Pokaż więcej
Źródło :
Trials [Trials] 2021 Nov 03; Vol. 22 (1), pp. 765. Date of Electronic Publication: 2021 Nov 03.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms :
Induction Chemotherapy*
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/drug therapy
Aged ; Aminoglycosides/adverse effects ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Benzimidazoles ; Gemtuzumab ; Humans ; Middle Aged ; Phenylurea Compounds
Czasopismo naukowe
Tytuł :
Women are predisposed to early dose-limiting toxicities during adjuvant CAPOX for colorectal cancer.
Autorzy :
Nozawa H; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kawai K; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Sasaki K; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Murono K; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Emoto S; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yokoyama Y; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Abe S; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kishikawa J; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Nagai Y; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Sonoda H; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Anzai H; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Ozawa T; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Ishihara S; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Pokaż więcej
Źródło :
International journal of clinical practice [Int J Clin Pract] 2021 Nov; Vol. 75 (11), pp. e14863. Date of Electronic Publication: 2021 Sep 18.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*
Colorectal Neoplasms*/drug therapy
Capecitabine/therapeutic use ; Chemotherapy, Adjuvant ; Female ; Fluorouracil/therapeutic use ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Oxaliplatin/therapeutic use
Czasopismo naukowe
Tytuł :
The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study.
Autorzy :
Takeshita E; Department of Surgery, Saitama Medical Center, Dokkyo University, Kosihgaya, Japan.
Ishibashi K; Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Koda K; Department of Surgery, Teikyo University Chiba Medical Center, Ichihara, Japan.
Oda N; Colo-Proctological Institute, Matsuda Hospital, Hamamatsu, Japan.
Yoshimatsu K; Department of Surgery, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
Sato Y; Department of Surgery, Toho University Sakura Medical Center, Sakura, Japan.
Oya M; Department of Surgery, Saitama Medical Center, Dokkyo University, Kosihgaya, Japan.
Yamaguchi S; First Department of Surgery, Dokkyo Medical University, Mibu, Japan.
Nakajima H; Department of Oncology, Ageo Central General Hospital, Ageo, Japan.
Momma T; Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima, Japan.
Maekawa H; Department of Surgery, Juntendo University Shizuoka Hospital, Izunokuni, Japan.
Tsubaki M; Department of Surgery, Yuai Memorial Hospital, Koga, Japan.
Yamada T; Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan.
Kobayashi M; Cancer Treatment Center, Kochi Medical School Hospital, Nankoku, Japan.
Tanakaya K; Department of Surgery, Iwakuni Clinical Center, Iwakuni, Japan.
Ishida H; Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan. .
Pokaż więcej
Źródło :
Surgery today [Surg Today] 2021 Aug; Vol. 51 (8), pp. 1309-1319. Date of Electronic Publication: 2021 Feb 14.
Typ publikacji :
Journal Article
MeSH Terms :
Chemotherapy, Adjuvant*
Sensory Receptor Cells*
Antineoplastic Agents/*adverse effects
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Colonic Neoplasms/*drug therapy
Colonic Neoplasms/*mortality
Neurotoxicity Syndromes/*epidemiology
Neurotoxicity Syndromes/*etiology
Oxaliplatin/*administration & dosage
Oxaliplatin/*adverse effects
Peripheral Nervous System Diseases/*etiology
Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Colonic Neoplasms/pathology ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Humans ; Leucovorin/administration & dosage ; Leucovorin/adverse effects ; Male ; Middle Aged ; Neoplasm Staging ; Organoplatinum Compounds/administration & dosage ; Organoplatinum Compounds/adverse effects ; Peripheral Nervous System Diseases/epidemiology ; Survival Rate ; Time Factors ; Treatment Outcome
SCR Protocol :
Folfox protocol
Czasopismo naukowe
Tytuł :
Improved response rate in patients with prognostically poor locally advanced rectal cancer after treatment with induction chemotherapy and chemoradiotherapy when compared with chemoradiotherapy alone: A matched case-control study.
Autorzy :
Voogt ELK; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands. Electronic address: .
Schaap DP; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands.
van den Berg K; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands.
Nieuwenhuijzen GAP; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands.
Bloemen JG; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands.
Creemers GJ; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands.
Willems J; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands.
Cnossen JS; Department of Radiation Oncology, Catharina Hospital, Eindhoven, the Netherlands.
Peulen HMU; Department of Radiation Oncology, Catharina Hospital, Eindhoven, the Netherlands.
Nederend J; Department of Radiology, Catharina Hospital, Eindhoven, the Netherlands.
van Lijnschoten G; Department of Pathology, PAMM Laboratory for Pathology and Medical Microbiology, Eindhoven, the Netherlands.
Burger JWA; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands.
Rutten HJT; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.
Pokaż więcej
Źródło :
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2021 Sep; Vol. 47 (9), pp. 2429-2435. Date of Electronic Publication: 2021 May 18.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Induction Chemotherapy*
Neoadjuvant Therapy*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Rectal Neoplasms/*pathology
Rectal Neoplasms/*therapy
Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Bevacizumab/administration & dosage ; Capecitabine/administration & dosage ; Case-Control Studies ; Dose Fractionation, Radiation ; Fascia/pathology ; Female ; Fluorouracil/administration & dosage ; Humans ; Leucovorin/administration & dosage ; Lymphatic Metastasis ; Magnetic Resonance Imaging ; Male ; Neoplasm Invasiveness ; Neoplasm Staging ; Organoplatinum Compounds/administration & dosage ; Oxaliplatin/administration & dosage ; Prognosis ; Rectal Neoplasms/diagnostic imaging ; Rectal Neoplasms/surgery ; Response Evaluation Criteria in Solid Tumors ; Retrospective Studies ; Treatment Outcome ; Tumor Burden ; Watchful Waiting
SCR Protocol :
Folfox protocol
Czasopismo naukowe
Tytuł :
Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer.
Autorzy :
Manning-Geist BL; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA. .; Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. .
Sullivan MW; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA.; Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Sarda V; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA.
Gockley AA; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.
Del Carmen MG; Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Matulonis U; Dana-Farber Cancer Institute, Boston, MA, USA.
Growdon WB; Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Horowitz NS; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.
Berkowitz RS; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.
Clark RM; Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Worley MJ Jr; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA.; Dana-Farber Cancer Institute, Boston, MA, USA.
Pokaż więcej
Źródło :
Annals of surgical oncology [Ann Surg Oncol] 2021 Oct; Vol. 28 (11), pp. 6705-6713. Date of Electronic Publication: 2021 Mar 08.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/pathology
Carcinoma, Ovarian Epithelial/drug therapy ; Carcinoma, Ovarian Epithelial/pathology ; Chemotherapy, Adjuvant ; Cytoreduction Surgical Procedures ; Disease-Free Survival ; Female ; Humans ; Infusions, Parenteral ; Neoplasm Staging ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Management of suboptimal response to induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Re-induction therapy or direct to Radiotherapy?
Autorzy :
Liu T; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
Liu LT; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
Lin JY; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
Shen BW; Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, PR China.
Guo SS; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
Liu SL; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
Sun XS; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
Liang YJ; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
Luo MJ; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
Li XY; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
Chen QY; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: .
Tang LQ; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: .
Mai HQ; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China. Electronic address: .
Pokaż więcej
Źródło :
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2021 Oct; Vol. 163, pp. 185-191. Date of Electronic Publication: 2021 Aug 26.
Typ publikacji :
Journal Article
MeSH Terms :
Induction Chemotherapy*
Nasopharyngeal Neoplasms*/drug therapy
Nasopharyngeal Neoplasms*/radiotherapy
Antineoplastic Combined Chemotherapy Protocols ; Chemoradiotherapy ; Cisplatin/therapeutic use ; Humans ; Nasopharyngeal Carcinoma/drug therapy ; Nasopharyngeal Carcinoma/radiotherapy ; Neoplasm Recurrence, Local ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Pegteograstim prophylaxis for chemotherapy-induced neutropenia and febrile neutropenia: a prospective, observational, postmarketing surveillance study in Korea.
Autorzy :
Cheon J; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877 Bangeojinsunwhandoro, Dong-gu, Ulsan, 44033, Republic of Korea.
Im HS; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877 Bangeojinsunwhandoro, Dong-gu, Ulsan, 44033, Republic of Korea.
Shin HJ; Division of Hematology-Oncology, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea.
Kim I; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Lee WS; Department of Hematology and Oncology, Inje University Busan Paik Hospital, Busan, Republic of Korea.
Lee KH; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Park SK; Department of Hematology and Oncology, Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea.
Kim MK; Department of Hematology and Oncology, Yeungnam University College of Medicine, Deagu, Republic of Korea.
Choi UJ; Department of Hematology and Oncology, Wonkwang University Hospital, Iksan, Republic of Korea.
Kim JH; Department of Hematology and Oncology, Kangnam Sacred-Heart Hospital, Seoul, Republic of Korea.
Lee I; Department of Hematology and Oncology, Catholic Kwandong University International ST. Mary's Hospital, Gangneung, Republic of Korea.
Jo JC; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877 Bangeojinsunwhandoro, Dong-gu, Ulsan, 44033, Republic of Korea. .
Pokaż więcej
Źródło :
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2021 Sep; Vol. 29 (9), pp. 5383-5390. Date of Electronic Publication: 2021 Mar 08.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Breast Neoplasms*/drug therapy
Chemotherapy-Induced Febrile Neutropenia*/epidemiology
Chemotherapy-Induced Febrile Neutropenia*/prevention & control
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide/adverse effects ; Doxorubicin/therapeutic use ; Female ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Humans ; Male ; Middle Aged ; Prospective Studies ; Republic of Korea ; Young Adult
Czasopismo naukowe
Tytuł :
Assessment of different induction chemotherapy regimens in locally advanced nasopharyngeal carcinoma: Meta-analysis.
Autorzy :
Guan H; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
He Y; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Su Y; West China Hospital, Sichuan University, Chengdu, China.
Wei Z; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Liu Z; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Wang J; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
He L; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Mu X; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Li R; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Hu X; Department of Nursing, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Peng X; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Pokaż więcej
Źródło :
Head & neck [Head Neck] 2021 Aug; Vol. 43 (8), pp. 2332-2341. Date of Electronic Publication: 2021 Mar 31.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
MeSH Terms :
Induction Chemotherapy*
Nasopharyngeal Neoplasms*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bayes Theorem ; Chemoradiotherapy ; Cisplatin/therapeutic use ; Humans ; Nasopharyngeal Carcinoma/drug therapy
Czasopismo naukowe
Tytuł :
Use of wide-spectrum antimicrobials with blood culture tests during chemotherapy as an accurate marker of febrile neutropenia in the DPC database: A validation study.
Autorzy :
Matsuda K; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan. Electronic address: .
Ise M; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Shimura A; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Honda A; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Masamoto Y; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Jo T; Division of Health Service Promotion, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Yasunaga H; Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Kurokawa M; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan; Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Pokaż więcej
Źródło :
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy [J Infect Chemother] 2021 Oct; Vol. 27 (10), pp. 1541-1542. Date of Electronic Publication: 2021 Jul 20.
Typ publikacji :
Letter
MeSH Terms :
Anti-Infective Agents*
Chemotherapy-Induced Febrile Neutropenia*
Febrile Neutropenia*/diagnosis
Febrile Neutropenia*/drug therapy
Antineoplastic Combined Chemotherapy Protocols ; Blood Culture ; Humans ; Vincristine
Opinia redakcyjna
Tytuł :
Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
Autorzy :
Chen FP; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-Sen University Cancer Center, No. 651 Dongfeng Eastern Road, Guangzhou, 510060, China.
Luo YS; Department of Radiation Oncology, Guangzhou Concord Cancer Center, Guangzhou, 510045, Guangdong, China.
Chen K; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-Sen University Cancer Center, No. 651 Dongfeng Eastern Road, Guangzhou, 510060, China.
Li JY; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-Sen University Cancer Center, No. 651 Dongfeng Eastern Road, Guangzhou, 510060, China.
Huo LQ; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-Sen University Cancer Center, No. 651 Dongfeng Eastern Road, Guangzhou, 510060, China.
Shi L; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-Sen University Cancer Center, No. 651 Dongfeng Eastern Road, Guangzhou, 510060, China.
Ou-Yang Y; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-Sen University Cancer Center, No. 651 Dongfeng Eastern Road, Guangzhou, 510060, China.
Cao XP; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-Sen University Cancer Center, No. 651 Dongfeng Eastern Road, Guangzhou, 510060, China. Electronic address: .
Pokaż więcej
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Jul; Vol. 151, pp. 63-71. Date of Electronic Publication: 2021 May 05.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Induction Chemotherapy*/adverse effects
Induction Chemotherapy*/mortality
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cell-Free Nucleic Acids/*blood
DNA, Viral/*blood
Epstein-Barr Virus Infections/*virology
Herpesvirus 4, Human/*genetics
Nasopharyngeal Carcinoma/*drug therapy
Nasopharyngeal Neoplasms/*drug therapy
Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemoradiotherapy ; Databases, Factual ; Disease-Free Survival ; Epstein-Barr Virus Infections/blood ; Epstein-Barr Virus Infections/mortality ; Female ; Humans ; Male ; Middle Aged ; Nasopharyngeal Carcinoma/mortality ; Nasopharyngeal Carcinoma/secondary ; Nasopharyngeal Carcinoma/virology ; Nasopharyngeal Neoplasms/mortality ; Nasopharyngeal Neoplasms/pathology ; Nasopharyngeal Neoplasms/virology ; Neoplasm Staging ; Progression-Free Survival ; Radiotherapy, Intensity-Modulated ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Time Factors ; Viral Load
Czasopismo naukowe
Tytuł :
Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer.
Autorzy :
Selle F; Service d'oncologie médicale Groupe hospitalier Diaconesses-Croix-Saint-Simon 75020 Paris, France; Groupe d'investigateurs nationaux pour les études des cancers de l'ovaire, 8 rue Lamenais, 75008 Paris, France. Electronic address: .
Alexandre J; Groupe d'investigateurs nationaux pour les études des cancers de l'ovaire, 8 rue Lamenais, 75008 Paris, France; AP-HP, centre - université de Paris, Hôpital Cochin, Paris, France.
Prulhière K; Groupe d'investigateurs nationaux pour les études des cancers de l'ovaire, 8 rue Lamenais, 75008 Paris, France; Service d'oncologie, polyclinique de Courlancy, Reims, France.
Kalbacher E; Groupe d'investigateurs nationaux pour les études des cancers de l'ovaire, 8 rue Lamenais, 75008 Paris, France; Service d'oncologie médicale, CHRU Besançon, France.
Ray-Coquard I; Groupe d'investigateurs nationaux pour les études des cancers de l'ovaire, 8 rue Lamenais, 75008 Paris, France; Département d'oncologie médicale, Centre Léon-Bérard, université Claude-Bernard Lyon 1 69008 Lyon, France.
Leary A; Groupe d'investigateurs nationaux pour les études des cancers de l'ovaire, 8 rue Lamenais, 75008 Paris, France; Service d'oncologie médicale, institut Gustave-Roussy, Villejuif, France.
Pokaż więcej
Corporate Authors :
pour le groupe GINECO
Źródło :
Bulletin du cancer [Bull Cancer] 2021 Dec; Vol. 108 (9S1), pp. S5-S12.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Ovarian Epithelial/*drug therapy
Ovarian Neoplasms/*drug therapy
Algorithms ; Bevacizumab/therapeutic use ; Carboplatin/therapeutic use ; Carcinoma, Ovarian Epithelial/genetics ; Carcinoma, Ovarian Epithelial/pathology ; Chemotherapy, Adjuvant ; Drug Administration Schedule ; Female ; Genes, BRCA1 ; Genes, BRCA2 ; Humans ; Indazoles/therapeutic use ; Maintenance Chemotherapy ; Neoadjuvant Therapy ; Neoplasm Grading ; Neoplasm Staging ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology ; Paclitaxel/therapeutic use ; Phthalazines/therapeutic use ; Piperazines/therapeutic use ; Piperidines/therapeutic use ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł :
Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
Autorzy :
Yang Z; Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Cai Z; Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.; Shantou University Medical College, Shantou, Guangdong, China.
Cai Q; Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Hong Y; Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Zhang C; Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.; Shantou University Medical College, Shantou, Guangdong, China.
Huang K; Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.; Shantou University Medical College, Shantou, Guangdong, China.
Lin Z; Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Li M; Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Pokaż więcej
Źródło :
Cancer medicine [Cancer Med] 2021 Jun; Vol. 10 (12), pp. 3886-3895. Date of Electronic Publication: 2021 May 06.
Typ publikacji :
Clinical Trial, Phase II; Equivalence Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Chemoradiotherapy*/adverse effects
Chemoradiotherapy*/mortality
Induction Chemotherapy*/adverse effects
Induction Chemotherapy*/mortality
Radiotherapy, Intensity-Modulated*/adverse effects
Radiotherapy, Intensity-Modulated*/mortality
Nasopharyngeal Carcinoma/*therapy
Nasopharyngeal Neoplasms/*therapy
Adult ; Aged ; Anemia/epidemiology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Incidence ; Leukopenia/epidemiology ; Male ; Middle Aged ; Nasopharyngeal Carcinoma/mortality ; Nasopharyngeal Carcinoma/pathology ; Nasopharyngeal Neoplasms/mortality ; Nasopharyngeal Neoplasms/pathology ; Neoplasm Staging ; Progression-Free Survival ; Radiotherapy Dosage ; Time Factors ; Young Adult
Czasopismo naukowe
Tytuł :
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma.
Autorzy :
Forsberg PA; Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Rossi AC; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York, USA.
Boyer A; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York, USA.
Pearse RN; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York, USA.
Pekle KA; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York, USA.
Jayabalan D; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York, USA.
Lakritz S; Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Flicker K; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York, USA.
Ribadeneyra D; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York, USA.
Liotta B; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York, USA.
Ely S; Bristol-Myers Squibb, New York, New York, USA.
Boussi L; New York Medical College, Valhalla, New York, USA.
Allan JN; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York, USA.
Coleman M; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York, USA.
Niesvizky R; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York, USA.
Mark TM; Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2021 Dec 01; Vol. 96 (12), pp. 1554-1562. Date of Electronic Publication: 2021 Sep 04.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Clarithromycin/*therapeutic use
Dexamethasone/*therapeutic use
Lenalidomide/*therapeutic use
Multiple Myeloma/*drug therapy
Oligopeptides/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Clarithromycin/adverse effects ; Dexamethasone/adverse effects ; Female ; Humans ; Induction Chemotherapy ; Lenalidomide/adverse effects ; Maintenance Chemotherapy ; Male ; Middle Aged ; Multiple Myeloma/diagnosis ; Oligopeptides/adverse effects ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies